April 29, 2024 Malpractice Risk With Active Surveillance for Patients With Low-Risk Cancer The ASCO Post
June 12, 2024 Ribociclib Plus Endocrine Therapy vs Combination Chemotherapy in Premenopausal Women With HR-Positive, HER2-Negative Advanced Breast Cancer Final results from the phase II RIGHT Choice study indicate that ribociclib plus endocrine therapy significantly prolonged progression-free survival vs combination chemotherapy in premenopausal women ... The ASCO Post
June 11, 2024 Low-Risk Prostate Cancer: Disease-Free Survival With Hypofractionated vs Conventionally Fractionated Radiotherapy The ASCO Post
June 11, 2024 Novel Gamma-Delta T Cell–Based Therapy Plus Temozolomide Maintenance in Glioblastoma Multiforme The ASCO Post
June 11, 2024 Integrating Palliative Care Education Into Hematology-Oncology Fellowships The ASCO Post
June 12, 2024 Ribociclib Plus Endocrine Therapy vs Combination Chemotherapy in Premenopausal Women With HR-Positive, HER2-Negative Advanced Breast Cancer The ASCO Post
June 11, 2024 Low-Risk Prostate Cancer: Disease-Free Survival With Hypofractionated vs Conventionally Fractionated Radiotherapy The ASCO Post
June 11, 2024 Novel Gamma-Delta T Cell–Based Therapy Plus Temozolomide Maintenance in Glioblastoma Multiforme The ASCO Post
June 11, 2024 Integrating Palliative Care Education Into Hematology-Oncology Fellowships The ASCO Post
2 Can Artificial Intelligence Predict Treatment Response and Outcomes in Breast Cancer? The ASCO Post
3 Accelerated Aging May Be a Risk Factor for Early-Onset Cancers in Younger Generations The ASCO Post
6 Guideline Update Seeks to Aid Clinicians in the Selection of Systemic Treatments for Advanced Hepatocellular Carcinoma The ASCO Post
June 11, 2024 Novel Gamma-Delta T Cell–Based Therapy Plus Temozolomide Maintenance in Glioblastoma Multiforme The ASCO Post
June 11, 2024 Integrating Palliative Care Education Into Hematology-Oncology Fellowships The ASCO Post
June 10, 2024 Osimertinib Therapy Poised to Become New Standard of Care for Unresectable Stage III EGFR-Mutated NSCLC The ASCO Post
June 10, 2024 LEAP-001: Study Misses Endpoints but Still Shows Benefit for Lenvatinib/Pembrolizumab in Endometrial Cancer Subsets The ASCO Post
March 19, 2024 ChatGPT May Accurately Answer Common Patient Questions Regarding Gynecologic Cancer The ASCO Post
June 10, 2024 Innovative Staging System for De Novo Metastatic Breast Cancer Validated Internationally The ASCO Post
May 29, 2024 Innovative Staging System for De Novo Metastatic Breast Cancer Validated Internationally The ASCO Post
May 24, 2024 Study Reveals Potential Overtreatment of DCIS in Older Women With Limited Life Expectancy The ASCO Post